GLP-1 Drug Tirzepatide Boosts Skin Clearance and Weight Loss in Psoriasis Patients
A phase IIIb trial finds adding tirzepatide to standard psoriasis treatment nearly triples complete skin clearance and drives meaningful weight loss.
Summary
A randomized clinical trial called TOGETHER-PsO found that adding the GLP-1/GIP drug tirzepatide to the psoriasis medication ixekizumab dramatically improved outcomes for patients with plaque psoriasis and obesity. At 36 weeks, 27.1% of patients on the combination therapy achieved both complete skin clearance and at least 10% weight loss, compared to just 5.8% on ixekizumab alone. Complete skin clearance rates also improved, 40.6% versus 29%. Patients also saw benefits in triglycerides, blood pressure, and skin-related quality of life. The findings suggest that treating psoriasis alongside its metabolic comorbidities — particularly obesity — may become a new standard of care, expanding the already growing list of conditions where GLP-1 drugs are proving transformative.
Detailed Summary
Plaque psoriasis is not just a skin condition. It is deeply intertwined with obesity, metabolic syndrome, cardiovascular risk, and systemic inflammation — a reality that has long complicated treatment. A new phase IIIb randomized trial now offers compelling evidence that addressing both the immune and metabolic dimensions of psoriasis simultaneously produces meaningfully better outcomes than treating the skin alone.
The TOGETHER-PsO trial enrolled adults with difficult-to-treat plaque psoriasis who were also overweight or obese. Participants received either the biologic drug ixekizumab alone or ixekizumab combined with tirzepatide, the dual GLP-1 and GIP receptor agonist already approved for weight loss and diabetes. At 36 weeks, the combination group achieved the composite primary endpoint — complete skin clearance plus at least 10% weight loss — at a rate of 27.1%, compared to just 5.8% in the ixekizumab-only group. Complete skin clearance alone was also significantly higher in the combination group, at 40.6% versus 29%.
Beyond skin outcomes, patients on tirzepatide also showed improvements in triglycerides, blood pressure, and quality of life metrics related to their skin condition. These cardiometabolic benefits are particularly significant given that psoriasis is a recognized driver of cardiovascular risk, yet no existing psoriasis treatments are specifically indicated to reduce that risk.
The findings build on the companion TOGETHER-PsA trial, which showed similar benefits in psoriatic arthritis, and align with tirzepatide's expanding therapeutic footprint across sleep apnea, liver disease, and cardiovascular risk reduction.
Caveats include the open-label design, which prevents blinding and may introduce bias. The 36-week timeframe is relatively short for a chronic condition. Longer-term safety data and real-world effectiveness studies will be needed before widespread adoption. Nonetheless, the results have prompted calls for dermatologists to adopt a more integrated, metabolic approach to psoriasis management.
Key Findings
- Combination of tirzepatide plus ixekizumab achieved complete skin clearance and 10% weight loss in 27.1% vs 5.8% on ixekizumab alone
- Complete skin clearance rates improved to 40.6% with tirzepatide added versus 29% with ixekizumab alone
- Tirzepatide combination also lowered triglycerides and blood pressure, addressing psoriasis-linked cardiovascular risk
- No new safety signals identified; GI events and injection site reactions were the most common side effects
- 60% of psoriasis patients in a separate review qualified for GLP-1 therapy, suggesting broad potential applicability
Methodology
This is a news report from MedPage Today summarizing the TOGETHER-PsO phase IIIb randomized controlled trial published in JAMA Dermatology. The source is a credible medical news outlet covering peer-reviewed research. The trial was open-label, which is a notable methodological limitation, though the findings were statistically significant and published in a high-quality journal.
Study Limitations
The open-label trial design introduces potential for bias since neither patients nor clinicians were blinded to treatment assignment. The 36-week follow-up is insufficient to assess long-term durability, safety, or cardiovascular outcomes. Independent replication and real-world studies in broader psoriasis populations are needed before this becomes standard practice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.